Navigation Links
PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel
Date:7/10/2008

ANNAPOLIS, Md., July 10 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that Jordan P. Karp, J.D., has been appointed Senior Vice President & General Counsel, overseeing all legal and human resources matters for PharmAthene.

Mr. Karp joins PharmAthene with over 17 years of legal experience in a variety of areas, including SEC compliance, corporate governance, mergers and acquisitions, government and commercial contracting, and intellectual property.

Prior to joining the Company, Mr. Karp was employed by Constellation Energy Group, Inc., a diversified Fortune 125 energy company, from 2001 to 2007. From October 2002 to November 2007, Mr. Karp served as Vice President & General Counsel for one of Constellation Energy's primary operating divisions, Constellation NewEnergy, Inc., a leading retail marketer of electricity and natural gas. Mr. Karp established and managed the legal function for Constellation NewEnergy during a period of rapid growth, in which annual revenues for Constellation's retail energy marketing segment increased from $2.6 billion in 2003 to $9.1 billion in 2007.

Before his tenure at Constellation, Mr. Karp held in-house legal positions of increasing responsibility at MCI Communications Corp., Guilford Pharmaceuticals Inc., and Mentor Technologies Group, Inc., where Mr. Karp served as Vice President, General Counsel & Corporate Secretary. Following a one year judicial clerkship on the U.S. Third Circuit Court of Appeals, Mr. Karp started his legal career as an associate attorney with the international law firm, Hogan & Hartson LLP, focusing
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PharmAthene Reports First Quarter 2008 Financial Results
2. PharmAthene to Host First Quarter 2008 Conference Call and Webcast on Tuesday, May 13, 2008
3. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
4. PharmAthene Reports Year-End 2007 Financial Results
5. Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthenes Protexia(R) Program
6. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
7. PharmAthene to Delay Release of Full Year 2007 Financial Results
8. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
9. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
10. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
11. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Since the cloning of Dolly the Sheep over a decade ... promising way to generate human, patient-specific stem cells for therapeutic ... efforts to substitute animal oocytes. However, a new study published ... 2009 issue of Cloning and Stem Cells , a ...
... its 20 years of experience as a leader in ... is offering free microbial identification testing , along ... attendees visiting the Microtest exhibit, #828, at MD&M West ... range of laboratory testing and validation services - and ...
... WALTHAM, Mass., Feb. 2 Repligen Corporation (Nasdaq: ... and Chief Executive Officer, Walter C. Herlihy, Ph.D., will ... Monday, February 9th, 2009 at 11:30 a.m. EST at ... live audio webcast of the presentation will be available ...
Cached Biology Technology:Animal Eggs Not Suitable Substitutes to Produce Stem Cells 2Animal Eggs Not Suitable Substitutes to Produce Stem Cells 3Microtest Labs Offers Free Microbial Identification Testing, Free Shipping on Other Tests, to MD&M West Attendees 2Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST 2
(Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
(Date:12/17/2014)... 16, 2014 Research and Markets ... the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend ... for medical sensors in biomedical applications. Chemical sensors ... and correct diagnosis during surgical procedures. The Global ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... , BIRMINGHAM, Ala. A new study at the University ... and abdominal obesity, which has been linked to an increased ... that in a sample of young adults during a 15-year ... gained weight at a faster rate than others in the ...
... -- CoLucid Pharmaceuticals, Inc., ("CoLucid"), an innovative biotechnology ... disorders, today announced that its investigational first-in-class Neurally ... COL-144), a selective 5-HT1F receptor agonist, was effective ... as documented in a Phase IIb study. Results ...
... the 2010 International Conference on Emerging Infectious Diseases (ICEID), ... Regency, Atlanta, Georgia. The meeting is being organized ... the American Society for Microbiology, the Council of State ... and the World Health Organization. The International Conference ...
Cached Biology News:UAB study confirms link between depression, abdominal obesity 2CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks 22010 International Conference on Emerging Infectious Diseases 2
...
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
... l-[35S]in vitro cell labeling mix, ... *Aqueous solution stabilized with 0.1% ... pyridine 3,4-dicarboxylic acid. *Amino acid ... labeling containing l-[35S]Methionine and l-[35S]Cysteine. ...
...
Biology Products: